Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel …
J Vestbo, A Papi, M Corradi, V Blazhko, I Montagna… - The Lancet, 2017 - thelancet.com
Background Limited data are available for the efficacy of triple therapy with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind …
D Singh, A Papi, M Corradi, I Pavlišová, I Montagna… - The Lancet, 2016 - thelancet.com
Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
Once-daily single-inhaler triple versus dual therapy in patients with COPD
DA Lipson, F Barnhart, N Brealey… - … England Journal of …, 2018 - Mass Medical Soc
Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease
DA Lipson, H Barnacle, R Birk, N Brealey… - American journal of …, 2017 - atsjournals.org
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
SJ Pascoe, DA Lipson, N Locantore… - European …, 2016 - Eur Respiratory Soc
Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …
Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis
Y Zheng, J Zhu, Y Liu, W Lai, C Lin, K Qiu, J Wu, W Yao - Bmj, 2018 - bmj.com
Objective To compare the rate of moderate to severe exacerbations between triple therapy
and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease …
and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease …
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
L Vanfleteren, LM Fabbri, A Papi… - … journal of chronic …, 2018 - Taylor & Francis
Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
M Cazzola, P Rogliani, L Calzetta… - European Respiratory …, 2018 - Eur Respiratory Soc
We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …